Nanjing Leads Biolabs Co., Ltd. - B - H Shares Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by ZUO HONGGANG, was filed 04 Aug 2026.
Nanjing Leads Biolabs Co., Ltd. - B - H Shares: what insiders have been doing
This page follows insider dealings at Nanjing Leads Biolabs Co., Ltd. - B - H Shares as filed with HKEX, a company from the Health Care sector. From 2 November 2025 to 2 November 2026, the disclosure feed for Nanjing Leads Biolabs Co., Ltd. - B - H Shares logged 16 filings by 4 insiders.
Open-market activity splits into 6 purchases totalling €157k and 10 sales totalling €8.0M; 3 insiders sit on the buying side and 4 insiders on the selling side. No amount is published for 11 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. On the buying side, the filings list 3 senior executives among the declarants. Biggest ticket of the year: €6.0M, sold by Kang Xiaoqiang and made public on 21 September 2026 (0.66% of market cap).
Across the 1,323 companies tracked on its exchange, the median is 4 filings; at 16 filings, this issuer sits above that mark. Over the whole record (from 2026), the tally stands at 6 purchases and 10 sales.
The latest purchase dates back some time: it was published 96 days ago, on 4 August 2026. Filings reach the HKEX feed a median of 5 days after the trade. This delay matters because a trade only becomes useful information once it is public. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- +6.8%Entry HK$5.85 · Close at T+30 HK$6.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 16,500 shares@ HK$43.672ShareXHKGHKEX:DA20261030E00388
- 16,500 sharesShareXHKGHKEX:DA20261030E00370
- 859,100 shares@ HK$63.69040.66% mcap76.4% of flowShareXHKGHKEX:DA20260918E00643
- 859,100 sharesShareXHKGHKEX:DA20260918E00661
- 312,900 sharesShareXHKGHKEX:DA20260805E00552
- 312,900 shares@ HK$53.80723.6% of flowShareXHKGHKEX:DA20260805E00574
- 3,500 shares@ HK$53.1613.1% of flowShareXHKGHKEX:DA20260804E00066Canonical exit: 29 Oct 2026 (T+90)
- 24,500 shares@ HK$49.9386.9% of flowShareXHKGHKEX:DA20260804E00065Canonical exit: 28 Oct 2026 (T+90)
- 198,891 sharesShareXHKGHKEX:DA20260702E00596Canonical exit: 29 Sept 2026 (T+90)
- 6,765,170 sharesShareXHKGHKEX:DA20260616E00076
- 14,976,377 sharesShareXHKGHKEX:DA20260609E00053
- 1,423,938 sharesShareXHKGHKEX:DA20260609E00099
- 14,976,377 sharesShareXHKGHKEX:DA20260609E00220
- 14,976,377 sharesShareXHKGHKEX:DA20260609E00052Canonical exit: 2 Sept 2026 (T+90)
- 1,423,938 sharesShareXHKGHKEX:DA20260609E00098Canonical exit: 2 Sept 2026 (T+90)
- 14,976,377 sharesShareXHKGHKEX:DA20260609E00219Canonical exit: 2 Sept 2026 (T+90)
16 of 16 declarations
About Nanjing Leads Biolabs Co., Ltd. - B - H Shares
Nanjing Leads Biolabs Co., Ltd. is a company focused on the development of biopharmaceutical products. It specializes in research and production of innovative solutions for the healthcare sector.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
